tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Fibroadenoma D018226 2 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Glucose Intolerance D018149 13 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Hypophosphatemia D017674 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Mucinoses D017520 2 associated lipids
Pityriasis Lichenoides D017514 2 associated lipids
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Porokeratosis D017499 1 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Hyperpigmentation D017495 11 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Polymyositis D017285 1 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Liver Failure, Acute D017114 11 associated lipids
IgG Deficiency D017099 1 associated lipids
IgA Deficiency D017098 2 associated lipids
Liver Failure D017093 5 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Critical Illness D016638 13 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Foot Ulcer D016523 4 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Fungemia D016469 2 associated lipids
Sweet Syndrome D016463 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Vestibular Diseases D015837 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
HIV Infections D015658 20 associated lipids
Histiocytosis D015614 2 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Weight Loss D015431 56 associated lipids
Weight Gain D015430 101 associated lipids
Reperfusion Injury D015427 65 associated lipids
Scleritis D015423 3 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Discitis D015299 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Dementia, Vascular D015140 7 associated lipids
Wounds, Stab D014951 3 associated lipids
West Nile Fever D014901 1 associated lipids
Vomiting D014839 21 associated lipids
Vitiligo D014820 2 associated lipids
Vision Disorders D014786 10 associated lipids
Viremia D014766 4 associated lipids
Venous Insufficiency D014689 2 associated lipids
Vasculitis D014657 14 associated lipids
Vascular Diseases D014652 16 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
The discovery of FK-506 and U.S. development. 1991 Nephrol News Issues pmid:1720512
Zheng B et al. Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. 1991 Transplant. Proc. pmid:1703717
Mieles L et al. Interaction between FK506 and clotrimazole in a liver transplant recipient. 1991 Transplantation pmid:1721250
Yabuuchi H et al. Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. 1991 Transplant. Proc. pmid:1703718
First International Congress on FK 506. August 21-24, 1991, Pittsburgh, PA. 1991 Transplant. Proc. pmid:1721253
Goto T et al. FK 506: historical perspectives. 1991 Transplant. Proc. pmid:1721254
Farghali H et al. Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. 1991 Transplant. Proc. pmid:1721283
Farghali H et al. A biochemical and 31P-NMR investigation of the effect of FK 506 and cyclosporine pretreatment on immobilized hepatocytes perifused with ethanol. 1991 Transplant. Proc. pmid:1721284
Farghali H et al. FK 506 modulates D-galactosamine-induced hepatitis in rats. 1991 Transplant. Proc. pmid:1721285
Zeevi A et al. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. 1991 Transplant. Proc. pmid:1721315
Matsuura T et al. Beneficial immunosuppressive effect of combined use of FK 506 and cyclosporine assessed by proliferative responses of cloned human T cells. 1991 Transplant. Proc. pmid:1721316
Jiang H et al. Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. 1991 Transplant. Proc. pmid:1721317
Yagihashi A et al. The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721318
Jain AB et al. Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. 1991 Transplant. Proc. pmid:1721347
Takaya S et al. Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. 1991 Transplant. Proc. pmid:1721348
Morel P et al. Liver retransplantation in adults: overall results and determinant factors affecting the outcome. 1991 Transplant. Proc. pmid:1721349
Perico N et al. FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. 1991 Transplant. Proc. pmid:1721378
Mieles L et al. Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. 1991 Transplant. Proc. pmid:1703362
Wagner K et al. Effect of FK 506 on excretion of urinary enzymes in rats. 1991 Transplant. Proc. pmid:1721379
Warty V et al. Distribution of FK 506 in plasma lipoproteins in transplant patients. 1991 Transplant. Proc. pmid:1703363
Prasad SJ et al. In vitro effects of cyclosporine and FK 506 on the renal cortex. 1991 Transplant. Proc. pmid:1721380
Kusne S et al. Early infections in kidney transplant recipients under FK 506. 1991 Transplant. Proc. pmid:1703364
Yamada K et al. Short-term FK 506-induced morphological changes in rat kidneys. 1991 Transplant. Proc. pmid:1721381
Moutabarrik A et al. FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. 1991 Transplant. Proc. pmid:1721382
Ricordi C et al. Human islet allotransplantation under FK 506. 1991 Transplant. Proc. pmid:1721410
Tze WJ et al. Long-term survival of islet allografts in diabetic rats treated with FK 506. 1991 Transplant. Proc. pmid:1721411
Wang X et al. Intraportal FK 506 improves intrahepatic islet allograft survival. 1991 Transplant. Proc. pmid:1721412
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation in rats. 1991 Transplant. Proc. pmid:1721413
Wiederrecht G et al. FKB1 encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1704127
Ziccardi VB et al. Maxillofacial considerations in orthotopic liver transplantation. 1991 Oral Surg. Oral Med. Oral Pathol. pmid:1704494
Bierer BE et al. The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. 1991 Eur. J. Immunol. pmid:1705513
Heitman J et al. FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1705713
Yokomise H et al. Immunosuppressive effects of FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721442
Hasegawa S et al. FK 506 and cyclosporine: effects and side effects in canine lung transplantation. 1991 Transplant. Proc. pmid:1721443
Wada H et al. Dose response to FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721444
Shiraki K et al. Effect of FK-506 on replication of human cytomegalovirus in vitro. 1991 J. Antibiot. pmid:1712008
Sigal NH et al. Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A. 1991 Transplant. Proc. pmid:1712132
Fung JJ et al. Current status of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1712133
Francavilla A et al. Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506. 1991 Hepatology pmid:1712337
Sakai K et al. The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents. 1991 Brain Res. pmid:1723023
Forrest MJ et al. FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. 1991 Biochem. Pharmacol. pmid:1716098
Weaver JL et al. Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. 1991 Immunopharmacol Immunotoxicol pmid:1723084
DiLella AG and Craig RJ Exon organization of the human FKBP-12 gene: correlation with structural and functional protein domains. 1991 Biochemistry pmid:1716149
Burres NS et al. Dunaimycins, a new complex of spiroketal 24-membered macrolides with immunosuppressive activity. III. Immunosuppressive activities of dunaimycins. 1991 J. Antibiot. pmid:1723403
McKeon F When worlds collide: immunosuppressants meet protein phosphatases. 1991 Cell pmid:1716181
Petros AM et al. NMR studies of an FK-506 analogue, [U-13C]ascomycin, bound to FKBP: conformation and regions of ascomycin involved in binding. 1991 J. Med. Chem. pmid:1716684
Morris RE Rapamycin: FK506's fraternal twin or distant cousin? 1991 Immunol. Today pmid:1715165
Baumann G et al. Cyclosporin A and FK-506 both affect DNA binding of regulatory nuclear proteins to the human interleukin-2 promoter. 1991 New Biol. pmid:1715185
Liu J et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. 1991 Cell pmid:1715244
Henderson DJ et al. Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. 1991 Immunology pmid:1715317